Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

Millions of people who bought DNA tests from genetic testing service 23andme have been urged to delete their personal data ...

D NA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire board of directors resigned over disagreements with the C ...

The news comes as Pfizer is trying to catch up with U.K.-based GlaxoSmithKline (GSK). Its RSV vaccine for adults was approved by the FDA in May. The company is already undergoing priority review with ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine.

Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...

GSK, Sanofi and CSL Ltd have secured $72 million from the US government to ramp up production of bird flu vaccines, Reuters ...

Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...

ViiV’s strategy for CAB LA for PrEP in L&MICs is to maximise rapid access and uptake for populations with highest unmet needs ...